首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Synthesis, evaluation and application of polycyclic fluorescent analogues as N-methyl-D-aspartate receptor and voltage gated calcium channel ligands.
【24h】

Synthesis, evaluation and application of polycyclic fluorescent analogues as N-methyl-D-aspartate receptor and voltage gated calcium channel ligands.

机译:N-甲基-D-天冬氨酸受体和电压门控钙通道配体的多环荧光类似物的合成,评估和应用。

获取原文
获取原文并翻译 | 示例
           

摘要

A series of polycyclic fluorescent ligands were synthesised and evaluated in murine striatal synaptoneurosomes for N-methyl-D-aspartate receptor (NMDAR) mediated calcium flux inhibition and inhibition of calcium influx through voltage gated calcium channels (VGCC). Amantadine (a) and N-(1-adamantyl)-1,3-propanediamine (c) substituted with 1-cyanoisoindole (3), indazole (5), dinitrobenzene (7, 8), dansyl (9, 10) and coumarin (11) moieties showed moderate to high inhibition of the NMDAR. A high degree of VGCC inhibition was observed for the cyanoisoindole compounds (3, 4) the dansyl compounds (9, 10) and the coumarin compound (12). Fluorophores conjugated to hydroxy-4-aza-8-oxoheptacyclotetradecane (13, 14) did not exhibit any significant VGCC inhibition, but the indazole conjugate (14) showed promising NMDAR activity. Dose response curves were calculated for selected NMDAR inhibitors (8-11) and N-[3-(1-adamantylamino)propyl]-5-dimethylaminonaphthalene-1-sulfonamide (10) exhibited the highest activity of the novel compounds. Compound 10 was further used as a fluorescent NMDAR ligand in a fluorescent competition assay utilizing MK-801, NGP1-01 and amantadine as known NMDAR inhibitors to demonstrate the possible applications of the novel fluorescent compounds. These small molecule fluorescent ligands can be considered as possible pharmacological tools in assay development and/or other investigations in the study of neurodegeneration.
机译:合成了一系列多环荧光配体,并在鼠纹状体突触神经小体中评估了N-甲基-D-天冬氨酸受体(NMDAR)介导的钙通量抑制和通过电压门控钙通道(VGCC)抑制钙流入。金刚烷胺(a)和N-(1-金刚烷基)-1,3-丙二胺(c)被1-氰基异吲哚(3),吲唑(5),二硝基苯(7、8),丹丹(9、10)和香豆素取代(11)部分显示对NMDAR的中度到高度抑制。对于氰基异吲哚化合物(3、4),丹磺酰基化合物(9、10)和香豆素化合物(12),观察到高度的VGCC抑制。与羟基-4-氮杂-8-氧庚七环十四烷(13、14)缀合的荧光团没有表现出任何显着的VGCC抑制作用,但吲唑缀合物(14)显示出有希望的NMDAR活性。计算所选NMDAR抑制剂(8-11)的剂量响应曲线,并且N- [3-(1-金刚烷基氨基)丙基] -5-二甲基氨基萘-1-磺酰胺(10)显示出新化合物的最高活性。在利用MK-801,NGP1-01和金刚烷胺作为已知的NMDAR抑制剂的荧光竞争试验中,化合物10还用作荧光NMDAR配体,以证明新型荧光化合物的可能应用。这些小分子荧光配体可以被认为是在神经变性研究中的测定开发和/或其他研究中可能的药理学工具。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号